ArticleJournal of the American Heart Association2025
External Validation of a Risk Prediction Model for Atherosclerotic Cardiovascular Diseases in a Large National Health-Checkup and Claim Database.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and External Validation of a Machine Learning Model for 10-Year Ischemic Stroke Risk Prediction in Diverse Populations.medRxiv : the preprint server for health sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Hisayama risk prediction model for atherosclerotic cardiovascular diseases (ASCVDs) has been featured in the latest Japanese preventive guidelines, yet it lacks external validation.
methodsA retrospective cohort study of 420 552 ASCVD-free individuals aged 40-74 years was performed using data from the national health checkup and administrative claim database recorded between April 2015 and November 2020. Incident cases of ASCVD were ascertained from
resultsDuring a median follow-up of 4.4 years, 3998 individuals developed ASCVD. The Hisayama ASCVD model had good predictive performance in the setting of the Japanese national health checkup. The original model performed well for estimating relative risks (hazard ratio, 32.73 [95% CI, 24.59-43.55] in the highest versus lowest decile) with a satisfactory discriminative ability (Uno's C-statistic, 0.759 [95% CI, 0.751-0.766]), while it tended to overestimate the predicted probability of ASCVD for the study population (calibration-in-the-large, 0.42 [95% CI, 0.41-0.44]). Improved performance was observed after recalibration by substituting the baseline survival rate (calibration-in-the-large, 1.00 [95% CI, 0.97-1.04]) and by refitting the model (calibration-in-the-large, 1.00 [95% CI, 0.97-1.03]; Uno's C-statistic, 0.766 [95% CI, 0.759-0.774]). The predictive performance was good across subgroups of age, sex, and type of insurance.
conclusionsThis external validation study demonstrated that the Hisayama ASCVD model had good predictive performance in the national health checkup setting in Japan, suggesting the use of the Hisayama ASCVD model for efficient risk stratification and risk communication in the nationwide health checkups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.